Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK002 in allergic conjunctivitis
NCT03379311Phase 1Completed
- Sponsor
- Allakos Inc.
- Start
- Feb 2018
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lirentelimab in atopic keratoconjunctivitis (AKC), Vernal Keratoconjunctivitis (VKC) and perennial allergic conjunctivitis (PAC), sponsored by Allakos Inc. Primary endpoint: Safety and Tolerability assessed by Clinical laboratory parameters and adverse events at Day 309. Started Feb 2018; status: completed.
02
Drugs
lirentelimab
03
Conditions
atopic keratoconjunctivitis (AKC)Vernal Keratoconjunctivitis (VKC)perennial allergic conjunctivitis (PAC)
Beyond the preview
Go deeper on NCT03379311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379311.